ENDOSPAN RECEIVES ADDITIONAL $25M FROM ARTIVION FOR NEXUS FDA APPROVAL PATH

Wednesday, July 03, 2024

Endospan, an Israeli-based privately-held company, has announced a new agreement with Artivion, Inc. for additional loans of up to $25 million to support the FDA approval process of their NEXUS® Stent Graft System.

This system is aimed at addressing thoracic aortic arch disease, including aneurysms and dissections, through minimally invasive endovascular procedures.

Their commitment to advancing minimally invasive solutions for aortic arch diseases, aiming to expand treatment options for patients facing complex anatomical challenges.

Thoracic aortic arch disease affects over 120,000 patients annually in the USA and Europe, with a significant portion remaining undiagnosed or untreated.

Traditional open surgical approaches carry high risks, especially for patients with complex anatomies or high perioperative risks.

The development of NEXUS represents a significant advancement by providing a minimally invasive alternative that reduces procedural complications, hospitalization time, and recovery periods.

Endospan's NEXUS system, the first approved branched endovascular system for aortic arch repair, targets a global market opportunity estimated at $600 million.

Currently, Endospan is conducting the TRIOMPHE IDE Study, which aims to evaluate the safety and effectiveness of NEXUS in treating thoracic aortic lesions.

Initial results from the study are promising, aligning with outcomes from previous clinical trials in Europe, demonstrating the potential for consistent, reliable outcomes in a minimally invasive setting.

This agreement with Artivion marks a significant step forward in Endospan's efforts to bring NEXUS to market, potentially transforming the landscape of aortic arch disease treatment by offering a less invasive option for patients and clinicians alike.





Source: prnewswire.com